Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
2021 · Journal of the American College of Cardiology · 131 citations
https://doi.org/10.1016/j.jacc.2021.04.102
A
Alexander Parkhomenko
National Scientific Center "M.D. Strazhesko Institute of Cardiology"(UA)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
3
Papers
292
Citations
3
h-index
3
i10-index
Alexander Parkhomenko is an academic researcher from National Scientific Center "M.D. Strazhesko Institute of Cardiology". The author has contributed to research in topics: Lipoproteins and Cardiovascular Health & Health Systems, Economic Evaluations, Quality of Life & Cerebrovascular and Carotid Artery Diseases. The author has an h-index of 3, co-authored 3 publications.
Papers by this author
worksLipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
2021 · Journal of the American College of Cardiology · 131 citations
https://doi.org/10.1016/j.jacc.2021.04.102
Evolocumab in Patients without a Previous Myocardial Infarction or Stroke
2025 · New England Journal of Medicine · 14 citations
https://doi.org/10.1056/nejmoa2514428
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat